Manifest Technologies, a developer of an AI-powered computational neuroimaging platform for CNS disease, unveiled the company after completing the initial funding and partnership with a top-five global pharmaceutical company. Supported by over $50 million of NIH-funded research at Yale, the scientific founders pioneered the NAIO technology, utilizing computational neuroscience and AI to enable a true precision medicine approach to mental illness and neurodegenerative diseases like Alzheimer’s and Parkinson’s.
Over one billion people on the planet now suffer from some form of brain disorder, with an estimated economic burden of as much as $8.5 trillion per year. And there is an urgent unmet need for more rapid and precise development of treatments delivered to the right person at the right time. Recent acquisitions in neuroscience highlight the need for tools that can optimize clinical trials and drive more efficient drug development based on precise neural targets.
Manifest was launched in 2021 by a group of leaders in computational psychiatry at Yale University School of Medicine to transform how CNS treatments are developed and delivered in the clinic.
The NAIO platform specifically enables CNS pharmaceutical companies to use human neuroimaging to unlock quantitative indication and patient selection decisions for clinical trials, saving billions of dollars in clinical development. And Manifest is actively working with Johnson & Johnson to deploy its solutions across several programs.
Along with Dr. Anticevic, the Manifest Board of Directors includes former CMO of Biohaven Pharmaceuticals, Robert Berman, and Co-Founder and Associate Professor of Psychological & Brain Sciences at Dartmouth College, John Murray.
KEY QUOTES:
“With a group of key initial investors and strategic partners we believe Manifest is ideally positioned to advance a platform that unifies computational clinical neuroscience with AI technology to guide the discovery and delivery of personalized treatments that are most likely to benefit patients at the individual level.”
– Manifest Technologies Founding CEO and Associate Professor of Psychiatry & Neuroscience at Yale University, Alan Anticevic
“We are thrilled to support Manifest’s efforts to quantitatively map the complexities of psychiatric disease. We recognize the tremendous potential of the NAIO platform to accelerate CNS clinical development and look forward to contributing to a future where tailored, individualized patient care is standard.”
– Ariane Tom, Managing Partner at Kaleida Capital
